K Ke ey y W Wo or rd ds s: : Urticaria; autoimmune diseases A An na ah ht ta ar r K Ke el li im me el le er r: : Ürtiker; otoimmün hastalık Cop yright © 2010 by Tür ki ye Kli nik le ri EDİTÖRE MEKTUP hro nic ur ti ca ri a (CU) is a com mon cli ni cal con di ti on in which ur tica ri a at tacks oc cur al most da ily and per sist mo re than six we eks. No un derl ying eti o logy can be de tec ted in many CU pa ti ents, and these ca ses are cal led chro nic idi o pat hic ur ti ca ri a (CI U).
The most re cent in for ma ti on on the pat ho ge ne sis of CU sug gests that many ca ses ha ve an un derl ying au to im mu ne di se a se. Ten to forty per cent of CU pa ti ents ha ve im mu nog lo bu lin (Ig) G-struc tu re an ti bo di es aga inst IgE or the alp ha cha in of high-af fi nity IgE re cep tors in the ir se rum. [1] [2] [3] Ad di ti onally, the facts that high le vels of au to an ti bo di es such as an ti-TG and an ti-TPO in CIU patients, and their res ponse to im mu no sup pres si ve tre at ments such as cyclos po ri ne A at trac ted at ten ti on to au to im mu nity's im por tan ce in CU's eti o logy. [4] [5] [6] [7] Chro nic im mu no lo gic inf lam ma ti on in an or gan might be a po ten ti al risk for de ve lo ping au to im mu nity in anot her or gan or tis su e be ca u se of gene tic pre dis po si ti on. 1 On the ba sis of this re la ti ons hip, we eva lu a ted an ti-TG, an ti-TPO and an ti-GPC an ti bo di es; vi ta min B12 le vels; and thyro id func ti ons in CI U pa ti ents and we in ves ti ga ted the re la ti ons hip bet we en CI U and au to im mu nity.
A to tal of 100 (71 fe ma les and 29 ma les) CI U pa ti ents and 20 (16 fe males and 4 ma les) he althy con trol sub jects were en rol led into the study. Demog rap hic cha rac te ris tics of the study gro up are sum ma ri zed in Tab le 1.
The da ta ob ta i ned we re eva lu a ted using the SPSS v11.0 sta tis ti cal softwa re pac ka ge. All va lu es we re ex pres sed as me an ± stan dard de vi a ti on. A Chi-squ a re analy sis test was per for med to eva lu a te the dis tri bu ti on of se xes bet we en gro ups and Mann Whit ney U test was used to com pa re the da ta of the pa ti ent and the con trol gro ups. The le vel of sta tis ti cal sig ni fi can ce was set at p< 0.05.
An ti-TPO an ti bo di es we re fo und po si ti ve in 15 of 100 pa ti ents, an ti-TG an ti bo di es in 23 of 100 pa ti ents and both an ti-TPO and an ti-TG an ti bo di es we re fo und po si ti ve in 11 of 100 pa ti ents. An ti-GPC an ti bo di es we re po si ti ve in 10 of 100 pa ti ents.
Only thre e pa ti ents had an ti-TPO, an ti-TG and anti-GPC an ti bo di es. No ne of the pa ti ents in the control gro up had po si ti ve an ti-TPO an ti bo di es, an ti-TG an ti bo di es or an ti-GPC an ti bo di es.
A com pa ri son of the va lu es in the pa ti ent and con trol gro ups re ve a led that me an se rum le vels of fre e T4, an ti-TG, an ti-TPO and an ti-GPC an ti body in the CI U pa ti ents we re sta tis ti cally sig ni fi cantly hig her than tho se in the con trol gro up (p= 0.012, 0.04, 0.02 and 0.05 res pec ti vely). No sig ni fi cant diffe ren ce was se en in me an se rum fre e T3 le vels (p> 0.05). Me an se rum TSH le vels we re sta tis ti cally signi fi cantly lo wer in CI U pa ti ents when compared to the con trol gro up (p= 0.010). Me an se rum vi ta min B12 le vels we re also sta tis ti cally sig ni fi cantly lo wer in CI U pa ti ents (p= 0.000) (Tab le 2).
Lez noff et al. first re por ted the re la ti ons hip bet we en CU and thyro id au to im mu nity in 1983. 5 The ir study inc lu ded 140 CU pa ti ents and 427 healthy con trols. The aut hors fo und that se rum thyro id mic ro so mal an ti body (an ti-TMA) ti ters we re hig her in CU pa ti ents (12.1%) than tho se in healthy con trols (5.6%). Six ye ars la ter, in 1989, in anot her study with 624 CU pa ti ents, Lez noff et al sho wed the pre sen ce of an ti-TMA and an ti-TG anti bo di es in 90 pa ti ents (14%). 6 They ob ser ved that 44 pa ti ents with high an ti body le vels al so sho wed cli ni cal signs of thyro id di se a se; tre at ment was star ted with 0.15-20 mg/day L-thyro xi ne in 46 pati ents (be ca u se of hypoth yro i dism or se ve re CU signs) and re mis si on oc cu red af ter 4-8 we eks. In addition, 13 CU pa ti ents had vi ti li go, ad re na li tis, pa rath yro i di tis and per ni ci o us ane mi a, and a re lati ons hip was no ted bet we en CU and ot her au toim mu ne di se a ses. 6 At the end of this study, aut hors sta ted that a sub gro up of CI U might be an au to immu ne di se a se of the skin and mu co us mem bra nes that is as so ci a ted with thyro id au to im mu nity, in the sa me way that di se a ses in the pol yen doc ri ne au to im mu ne di se a se spec trum were as so ci a ted with thyro id au to im mu nity. In the pre sent study, we es tab lis hed that the thyro id au to an ti bo di es were hig her than the se pre vi o us stu di es in the li te ra tu re in CI U pa ti ents.
The fol lo wing stu di es fo cu sed mostly on the re la ti on bet we en the CU's du ra ti on and the pre sence of thyro id an ti bo di es. To u bi et al, who pros pecti vely fol lo wed CU pa ti ents for fi ve-ye ars pe ri od, re por ted that CU at tacks con ti nu ed in 52% of those with po si ti ve thyro id au to an ti bo di es, but in only 16% of tho se with ne ga ti ve thyro id au to an ti bo di es, with a sta tis ti cally sig ni fi cant dif fe ren ce. 7 This study of the re la ti ons hip bet we en au to im mu nity and CU's du ra ti on and se ve rity, re ve a led that longlas ting CU re sults from the pro lon ged sti mu la ti on of T-cells fol lo wed by pro lon ged poly clo nal ac ti vati on,and the pro duc ti on of va ri o us cyto ki nes that co uld in du ce sec re ti on of au to an ti bo di es.
No nen doc ri ne or gan-spe ci fic au to im mu ne di se a ses as so ci a ted with au to im mu ne thyro id di se a se inc lu de per ni ci o us ane mi a, di a be tes mel li tus, primary scle ro sing cho lan gi tis, pri mary hyper pa rathyro i dism and vi ti li go. 1, [4] [5] [6] [7] Re cently, au to im mu ne mec ha nisms ha ve be en emp ha si zed in CI U's eti ology. Me te et al, 4 eva lu a ted vi ta min B12 le vels, anti-GPC an ti bo di es and thyro id au to an ti bo di es in CI U pa ti ents. They fo und that se rum vi ta min B12
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The number of patients (n) 100 20 Nor mal test va lu es in our la bo ra tory are as fol lows: fre e T3: 1.57-4.71 pg/mL; Fre e T4: 0.93-1.71 ng/dL; TSH: 0.27-4.2 µIU/mL; An ti-TPO <50 IU/mL; An ti-TG < 150 IU/mL; Vita min B12: 174-878 pg/mL; An ti-GPC< 15 IU/mL.
Kandi ve ark. Dermatoloji ve Veneroloji le vel was be low nor mal ran ge in 33% of CI U pa tients. Thyro id au to an ti bo di es we re fo und to be po si ti ve in 54.5% and an ti-GPC an ti bo di es we re fo und to be po si ti ve in 36.4%. They re por ted that the se da ta we re highly sta tis ti cally sig ni fi cant. The study sho wed no dif fe ren ce bet we en low and nor mal B12 le vels with re gard to IgG He li co bac ter pylo ri an tibody's in ci den ce and he ma to lo gi cal or ne u ro lo gi cal ma ni fes ta ti ons of B12 de fi ci ency. 4 The se re sults sup port the pre vi o us stu di es, which sug gest an auto im mu ne ba sis to CI U. In com pa ri son with this study, we fo und that an ti-GPC an ti bo di es we re also in cre a sed in re la ti vely low per cen ta ge (10%) of CI U pa ti ents.
In conc lu si on, we fo und that CI U pa ti ents had in cre a sed le vels of an ti-thyro id and an ti-GPC an ti bo di es. It sho uld be bor ne in mind that CI U can be together with au to im mu ne di se a ses, and spe ci fic en doc ri ne and im mu no lo gic tests sho uld be con duc ted to cla rify the di se a se's eti o logy, espe ci ally in pa ti ents who are re sis tant to tre atment.
